A workshop was convened by the US Food and Drug Administration and the American Association for Cancer Research to create recommendations for trial design and later stages of drug development in multiple myeloma.
Researchers hope their findings could lead to targeted interventions to improve cognitive outcomes in pediatric brain tumor survivors from families with low socioeconomic status.
Oncologists and patients should be aware of the potential manifestations of the COVID-19 vaccination on imaging and the consequences this might have on disease assessment, treatment monitoring, and decision-making.
The COVID-19 pandemic sheds new light on existing access challenges in preventive health care.
Ajai Chari, MD, of Mount Sinai Hospital in New York City, provides his perspective on the current state of care in multiple myeloma.
New NCCN guidelines for Wilms tumor contain up-to-date information on screening, diagnosis, risk stratification, and treatment for this rare childhood renal cancer.
Diabetes and metabolic syndrome represent two of the most common long-term complications in survivors of childhood cancer.
Xiuning Le, MD, PhD, discusses the future of tepotinib in the treatment of NSCLC. Dr Le is an author of a phase 2 study on tepotinib, a highly selective MET inhibitor.
To prove clinical benefit, the FDA requires manufacturers to conduct confirmatory trials, also known as a phase 4 studies.
An evaluation of a large dataset sought to determine use of imaging studies in children treated in children’s hospital emergency departments.
Photobiomodulation shows impressive results in pretrial use for treatment and prevention of treatment-associated mucositis in pediatric patients.
Researchers discuss the potential of enobosarm, a selective androgen receptor modulator, for the treatment of ER-positive breast cancer that has progressed on at least 1 previous endocrine therapy.
A retrospective study found that a radiomic-clinicopathologic nomogram performed better than other tools in predicting biochemical recurrence-free survival after surgery for prostate cancer.
A new algorithm developed by Canadian investigators aims to address underuse of cisplatin-based chemotherapy for muscle-invasive bladder cancer.
C. Andrew Kistler, MD, PharmD, examines existing data about bariatric surgery and the risk for subsequent colorectal cancer development.